All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.Following the completion of the tender offer, Merck completed the acquisition of ArQule today through a merger of Mercks wholly-owned subsidiary with and into ArQule in which all shares not tendered into the offer were cancelled and converted into the right to receive cash equal to the 20.00 offer price per share, without interest, less any applicable tax withholding.At the completion of the merger, ArQule became a wholly-owned subsidiary of Merck.The common stock of ArQule will no longer be listed or traded on the NASDAQ Global Select Market.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimers disease and infectious diseases including HIV and Ebola. This news release of Merck Co., Inc., Kenilworth, N.J., USA (the company) includes statements that are not statements of historical fact, or forward-looking statements, that are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the companys ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the companys patents and other protections for innovative products; and the exposure to litigation, including patent litigation, andor regulatory actions. Arqule Company Update Any ForwardThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. ![]() Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. We are called MSD everywhere, except in the United States and Canada where we are known as Merck Co Inc, Kenilworth, NJ USA.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |